Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05420064 · ClinicalTrials.gov registry record · NA
An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results
A NA study of BRCA1 Mutation and BRCA2 Mutation, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 8
- Study locations
NCT05420064 is a NA study of BRCA1 Mutation and BRCA2 Mutation that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 1,000 participants, above the 510-participant average among 15 other BRCA1 Mutation trials with a reported enrollment target (96% higher). The trial reports 8 study locations across 2 states.
The verdict
NCT05420064, a NA study of BRCA1 Mutation and BRCA2 Mutation, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to examine the impact of new cancer genetic counseling models that aim to increase patient engagement with the genetics team. To do this, the study consists of two trials to evaluate two related interventions. The first trial is the EfFORT Trial, which evaluates a cascade genetic testing intervention. Cascade testing is the process of offering genetic testing to people who are at risk of having inherited a possibly harmful gene change that has been found in their family. The study will look at how often genetic testing occurs when healthcare providers have permission to reach out to family members to recommend genetic testing and to help those who are interested get tested. The study will look at whether this cascade testing intervention is practical and effective. The study would like to see how this approach of healthcare providers reaching out directly to family members compares with the usual approach of patients telling their family members about the recommendation to get genetic testing. The second trial is the STRIVE Trial, which evaluates an intervention designed to help patients who receive an uncertain result from genetic testing (also called a "variant of uncertain significance") stay connected with their genetics care team, and to help patients and their primary care providers stay up-to-date about the meaning of uncertain genetic test results. The study will look at whether an intervention that consists of a study online portal for patients with uncertain genetic test results and their primary care providers will help them to stay up-to-date on the meaning of uncertain genetic test results. The study would like to see how this intervention compares to the usual approach of encouraging patients to re-contact their genetics care team on their own about a year after getting genetic testing."
Conditions Studied
Interventions
- BEHAVIORAL Standard of Care
- BEHAVIORAL Intervention Arm At-risk Relative/ARR Contacts
- BEHAVIORAL MyGene Portal
Study Locations (8)
New York
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- MSK at Ralph Lauren (Limited Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activity) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activity) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2022-12-01 |
| Est. Completion | 2026-11-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05420064
The ClinicalTrials.gov registry entry for NCT05420064 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 510-participant average among 15 other BRCA1 Mutation trials with a reported enrollment target (96% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with BRCA1 Mutation appearing as the primary indexed condition, and to 3 interventions - of which Standard of Care is the first listed.
NCT05420064 reports 8 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05420064 about?
NCT05420064 is a clinical study titled "An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results". The purpose of this study is to examine the impact of new cancer genetic counseling models that aim to increase patient engagement with the genetics team. To do this, the study consists of two trials to evaluate two related interventions. The first trial is the EfFORT Trial, which evaluates a cascad...
What is the current status of trial NCT05420064?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2022-12-01. Estimated completion is 2026-11-30.
What conditions does trial NCT05420064 study?
This clinical trial studies the following conditions: BRCA1 Mutation, BRCA2 Mutation, ATM Gene Mutation, MLH1 Gene Mutation, POLD1 Gene Mutation.
What interventions are being tested in trial NCT05420064?
The interventions under investigation include: Standard of Care (BEHAVIORAL), Intervention Arm At-risk Relative/ARR Contacts (BEHAVIORAL), MyGene Portal (BEHAVIORAL).
Who is sponsoring clinical trial NCT05420064?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05420064 being conducted?
This trial has 8 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for BRCA1 Mutation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy
RECRUITING · NA
-
FaCT Trial (Facilitated Cascade Testing Trial)
RECRUITING · NA
-
Decision Support for BRCA Testing in Ethnically Diverse Women
COMPLETED · NA
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
Combination Therapy in Cancers With Mutations in DNA Repair Genes
RECRUITING · Phase 1
-
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.